Pharmacokinetics and Safety of Vedolizumab Following Administration of a Single Intravenous Dose in Healthy Chinese Subjects

BACKGROUND AND OBJECTIVES: Vedolizumab is a humanized monoclonal antibody, indicated for the treatment of moderately to severely active ulcerative colitis (UC) or Crohn’s disease (CD), that specifically binds to the α4β7 integrin. The aim of this study was to assess the pharmacokinetics, safety, and...

Descripción completa

Detalles Bibliográficos
Autores principales: Xie, Ran, Zhao, Nan, Jia, Bo, Zhao, Xia, Cui, Yimin, Okamoto, Hiroyuki, Yang, Lili, Prokopienko, Alexander
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9823075/
https://www.ncbi.nlm.nih.gov/pubmed/36400983
http://dx.doi.org/10.1007/s13318-022-00804-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9823075/
https://www.ncbi.nlm.nih.gov/pubmed/36400983
http://dx.doi.org/10.1007/s13318-022-00804-6

Ejemplares similares